Literature DB >> 1180731

Myasthenia gravis and acetylcholine receptor. Effect of steroids in clinical course and cellular immune response to acetylcholine receptor.

O Abramsky, A Aharonov, D Teitelbaum, S Fuchs.   

Abstract

Lymphocytes from patients with myasthenia gravis (MG) were transformed when cultured in vitro with an acetylcholine receptor fraction extracted from the electric organ of an electric eel. Marked diminution of the cellular response to acetylcholine was shown in patients who improved clinically with prednisone treatment. The transient clinical deterioration during the first days of prednisone treatment was accompanied by a transient increase in lymphocyte response. These findings that an in vivo sensitization of lymphocytes to self-acetylcholine receptor may occur in MG, and that a cell-mediated autoimmune mechanism may be important in the pathogenesis of the neuromuscular block. The present observations indicate that prednisone provides a measure of immunosuppression in MG. The transient clinical deterioration during the first days of prednisone therapy may reflect an enhancement of cell reactivity by this drug.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1180731     DOI: 10.1001/archneur.1975.00490520054008

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  10 in total

Review 1.  Neurochemistry and behavior in man.

Authors:  G S Omenn
Journal:  West J Med       Date:  1976-12

2.  Steroids induce acetylcholine receptors on cultured human muscle: implications for myasthenia gravis.

Authors:  I Kaplan; B T Blakely; G K Pavlath; M Travis; H M Blau
Journal:  Proc Natl Acad Sci U S A       Date:  1990-10       Impact factor: 11.205

Review 3.  Myasthenia gravis as a prototype autoimmune receptor disease.

Authors:  A C Hoedemaekers; P J van Breda Vriesman; M H De Baets
Journal:  Immunol Res       Date:  1997       Impact factor: 2.829

4.  Specific involvement of peripheral T lymphocytes against acetylcholine receptors in myasthenia gravis.

Authors:  B M Conti-Tronconi; A Scotti; A Sghirlanzoni; F Clementi
Journal:  J Neurol Neurosurg Psychiatry       Date:  1983-09       Impact factor: 10.154

5.  Long-term effect of glucocorticosteroids on neuromuscular blocking in mice.

Authors:  W F Arts; H J Oosterhuis
Journal:  J Neurol Neurosurg Psychiatry       Date:  1977-07       Impact factor: 10.154

6.  Identification of T-cell epitopes of autoantigens using recombinant proteins; studies on experimental autoimmune myasthenia gravis.

Authors:  Y Zhang; S Frutiger; G J Hughes; M C Savoy; T Barkas
Journal:  Immunology       Date:  1990-12       Impact factor: 7.397

Review 7.  A practical guide to the recognition and management of myasthenia gravis.

Authors:  A Evoli; A P Batocchi; P Tonali
Journal:  Drugs       Date:  1996-11       Impact factor: 9.546

8.  Immune regulation of experimental myasthenia.

Authors:  S Fuchs; D Bartfeld; Z Eshhar; C Feingold; D Mochly-Rosen; D Novick; M Schwartz; R Tarrab-Hazdai
Journal:  J Neurol Neurosurg Psychiatry       Date:  1980-07       Impact factor: 10.154

Review 9.  Ocular myasthenia gravis. A critical review of clinical and pathophysiological aspects.

Authors:  N Sommer; A Melms; M Weller; J Dichgans
Journal:  Doc Ophthalmol       Date:  1993       Impact factor: 2.379

10.  Specific immunosuppression of experimental autoimmune myasthenia gravis by denatured acetylcholine receptor.

Authors:  D Bartfeld; S Fuchs
Journal:  Proc Natl Acad Sci U S A       Date:  1978-08       Impact factor: 11.205

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.